Increasing environmental distress is associated with a growing asthma incidence; no
treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes …

Aims Montelukast (MTK) is an antagonist of the cysteinyl leukotrienes receptor 1 widely used
to manage asthma symptoms among adults and children. However, it has been associated …

Background Recent observational studies suggest that the leukotriene receptor antagonist
montelukast may have neuropsychiatric adverse effects; however, results are conflicting …

Alzheimer's disease (AD) is the most common form of dementia. In particular,
neuroinflammation, mediated by microglia cells but also through CD8+ T-cells, actively …

Background: The United States Food and Drug Administration issued a black box warning
on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk …

Importance The evidence base for the association between montelukast and adverse
neuropsychiatric outcomes is mixed and inconclusive. Several methodological limitations …

Purpose Leukotriene receptor antagonists are used in asthma and rhinitis treatment.
Pharmacovigilance data have suggested an association between montelukast and …

Currently, there is no definitive cure for epilepsy. The available medications relieve
symptoms and reduce seizure attacks. The major challenge with the available antiepileptic …

Background Accumulative data links inflammation and immune dysregulation to the
pathophysiology of mental disorders; little is known regarding leukotrienes'(LTs) …

Montelukast, a leukotriene receptor antagonist, is approved by the United States Food and
Drug Administration (FDA) for the prophylaxis and long‐term treatment of asthma …